The NCPE believe that, at the submitted price, Abiraterone Acetate (Zytiga®) is not cost effective for the treatment of metastatic castration resistant prostate cancer in patients who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated
Eltrombopag (Revolade®) is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy Rapid Review Commenced Completed Outcome 10/01/2014 13/02/2014 Full Pharmacoeconomic Evaluation
The NCPE believe that when compared to alternative biological agents aflibercept may be considered cost saving.